Show an ad over header. AMP

The FDA plays defense on its coronavirus actions

The uproar over the FDA's authorization for the use of convalescent plasma in coronavirus patients is only partially about convalescent plasma. It's also about a vaccine that doesn't exist yet, and trust in the FDA's eventual stamp of approval.

The state of play: The FDA has been forced to defend itself on both fronts.


  • Peter Marks, who leads the relevant division within the FDA, said at a news conference yesterday that the evidence of plasma's effectiveness "more than adequately met" the standards for emergency use, noting that there is little question about its safety, per the Wall Street Journal.

And FDA commissioner Stephen Hahn, in an interview with Bloomberg's Drew Armstrong, owned up to a mistake in how he described the effectiveness of convalescent plasma while also addressing bigger-picture concerns about the FDA's independence.

  • "Yeah, I'm aware of it. I've listened to all the conversations," Hahn told Bloomberg when asked about political pressure. "But what I tell internally our folks is they need to make the decisions based upon the data. I have not reversed one of their decisions, nor do I intend to unless I think it's absolutely wrong."
  • Hahn also said he wasn't present when White House economic adviser Peter Navarro berated FDA officials as members of the "Deep State" and told them to "get on Trump Time."
  • He said he "would not participate in any decision that was made on anything other than the science."

Trump pushes to expand ban against anti-racism training to federal contractors

President Trump announced late Tuesday that the White House attempt to halt federal agencies' anti-racism training would be expanded to block federal contractors from "promoting radical ideologies that divide Americans by race or sex."

Why it matters: The executive order appears to give the government the ability to cancel contracts if anti-racist or diversity trainings focused on sexual identity or gender are organized. The memo applies to executive departments and agencies, the U.S. military, federal contractors and federal grant recipients.

Keep reading... Show less

GoodRx prices IPO at $33 per share, valued at $12.7 billion

GoodRx, a price comparison app for prescription drugs at local pharmacies, on Tuesday raised $1.14 billion in its IPO, Axios has learned.

By the numbers: GoodRx priced its shares at $33 a piece, above its $24-$28 per share offering range, which will give it an initial market cap of around $12.7 billion.

Keep reading... Show less

Scoop: Meadows puts agencies on notice about staff shake-up

White House chief of staff Mark Meadows told administration officials Monday to expect senior aides to be replaced at many government agencies, according to an internal email obtained by Axios.

Behind the scenes: Meadows asked the director of the White House Presidential Personnel Office John McEntee "to look at replacing the White House Liaisons (WHLs) at many of your agencies," according to the email. "John will be working with outgoing liaisons to explore other opportunities."

Keep reading... Show less

White House ricin package suspect allegedly urged Trump to "give up for this election"

A Canadian woman allegedly mailed a letter addressed to President Trump containing the poison ricin and the threat "give up and remove your application for this election," court papers filed Tuesday show.

Driving the news: Pascale Cecile Veronique Ferrier, 53, was arrested trying to enter New York from Canada on Sunday. She appeared briefly in a Buffalo, N.Y., courtroom where a judge entered a not guilty plea on her behalf to the charge of threatening the president, per CBC.

Keep reading... Show less

House Democrats, Trump administration strike deal to avert government shutdown

House Democrats have reached a deal with the Trump administration on legislation to fund the government through Dec. 11, Speaker Nancy Pelosi (D-Calif.) announced Tuesday.

Why it matters: The deal will avert a government shutdown when funding expires in eight days. Pelosi and House Majority Leader Steny Hoyer (D-Md.) said earlier that they hoped to hold a vote on the legislation on Tuesday evening.

Keep reading... Show less

Remote work won't kill your office

We can officially declare the 9-to-5, five-days-a-week, in-office way of working dead. But offices themselves aren't dead. And neither are cities.

The big picture: Since the onset of pandemic-induced telework, companies have oscillated between can't-wait-to-go-back and work-from-home-forever. Now, it's becoming increasingly clear that the future of work will land somewhere in the middle — a remote/in-person hybrid.

Keep reading... Show less

FBI: Foreign actors likely to sow disinformation about delays in election results

The FBI and Cybersecurity and Infrastructure Security Agency released a public service announcement on Tuesday warning that mail-in ballots "could leave officials with incomplete results on election night," and that foreign actors are likely to spread disinformation about the delays.

The bottom line: The agencies called on the public to "critically evaluate the sources of the information they consume and to seek out reliable and verified information from trusted sources," including state and local election officials.

Keep reading... Show less

The big business of immigrant detention

Around 70% of all immigration detention centers are run by private companies, including the one at the heart of a new whistleblower complaint that alleges systemic medical neglect and malpractice.

Axios Re:Cap digs into the business of immigrant detention, including oversight and profit incentives, with Jonathan Blitzer, a staff writer for the New Yorker who’s covered the subject for years.

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories